From 2015 to 2023, there was a decrease in the number of U.S. patients prescribed long-term opioid therapy, according to a study published online April 8 in t ...

A study prospectively evaluated functional outcomes in men with prostate cancer managed with active surveillance, surgery with or without nerve sparing, or radiation.

A novel risk score outperforms traditional tools in predicting kidney failure among individuals of African ancestry with high-risk APOL1 genotypes.

(HealthDay News) — The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small ...

Alongside Schwartz’s nomination, the administration also announced additional CDC picks, including Sean Slovenski as deputy director and chief operating officer; Dr. Jennifer Shuford as chief medical ...

Nearly half of responses from five popular chatbots were problematic, particularly about stem cells, athletic performance, and nutrition.

(HealthDay News) — A new U.S. Senate report, released by Sen. Bernie Sanders, found that drug companies involved in price deals with President Donald Trump have continued to raise prices on hundreds ...

FDA grants Priority Review to enfortumab vedotin plus pembrolizumab for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS risk.

MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy.

A trial compared patient-reported outcome measures after percutaneous nephrostomy vs JJ ureteric stent for urinary tract decompression in patients with obstructive stones.

Disproportionate increases seen across Black and Hispanic individuals, particularly in opioid-stimulant and opioid-only profiles.

No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.